Most patients with large cell lymphoma are cured with frontline chemoimmunotherapy. For
individuals with refractory disease and those who relapse after conventional therapies …

Introduction: Chimeric antigen receptor (CAR) T-cell therapy has shown durable responses
in 40-50% of patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). For …

The standard of care treatment strategy for patients with relapsed or refractory large B-cell
lymphoma (LBCL) has been high-dose chemotherapy followed by autologous stem cell …

Aggressive B-cell lymphomas that are primary refractory to, or relapse after, frontline
chemoimmunotherapy have a low cure rate with conventional therapies. Although high-dose …

Anti-CD19 chimeric antigen receptor T cell (CAR-T) therapy has transformed the care of
patients with relapsed/refractory large B cell lymphoma (LBCL). However, approximately …

Despite the success of CD19-targeted chimeric antigen receptor (CAR T)-cell therapy in
patients with relapsed/refractory large B-cell lymphoma (LBCL), there is a need for effective …

The goal of this review is to firstly address the concept of chimeric antigen receptor T-cell
(CAR T-cell) therapy and where it fits in the evolving landscape of the management of …

Adoptive cellular immunotherapy with anti CD19 chimeric antigen receptor (CAR)-T cell has
changed the treatment landscape in relapsed/refractory B cell lymphomas. They have …

CAR T-cells have transformed the therapeutic landscape for patients with relapsed/refractory
aggressive B-cell lymphomas. Currently, three CAR T-cell products are approved or soon to …

Chimeric antigen receptor (CAR) T-cell therapy has emerged as an option for
relapsed/refractory aggressive B-cell lymphomas that have failed 2 lines of therapy. Failures …